2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 17, 2010, Pages 1864-1873

  Papaioannou, Alexandra ^a   Morin, Suzanne ^c   Cheung, Angela M ^d   Atkinson, Stephanie ^b   Brown, Jacques P ^e   Feldman, Sidney ^d   Hanley, David A ^f   Hodsman, Anthony ^g   Jamal, Sophie A ^d   Kaiser, Stephanie M ^h   Kvern, Brent ⁱ   Siminoski, Kerry ^j   Leslie, William D ⁱ  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ETIDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

CANADA; CELLULITIS; ESOPHAGUS CANCER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; JAW OSTEONECROSIS; LIFESTYLE; LUNG EMBOLISM; NEPHROLITHIASIS; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VERTEBRA FRACTURE;

EID: 78649680817     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.100771     Document Type: Review

References (71)

1. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl):S1-34.
2. Cheung AM, Detsky AS. Osteoporosis and fractures: Missing the bridge? JAMA 2008;299:1468-70.
3. Bessette L, Ste-Marie LG, Jean S, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008;19:79-86.
4. Papaioannou A, Kennedy CC, Ioannidis G, et al. The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2009;20:703-14.
5. Ioannidis G, Papaioannou A, Hopman WM, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009; 181: 265-71.
6. Wiktorowicz ME, Goeree R, Papaioannou A, et al. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 2001;12:271-8.
7. Tosteson AN, Gottlieb DJ, Radley DC, et al. Excess mortality following hip fracture: the role of underlying health status. Osteoporos Int 2007;18:1463-72.
8. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82.
9. Papaioannou A, Giangregorio L, Kvern B, et al. The osteoporosis care gap in Canada. BMC Musculoskelet Disord 2004;5:11.
10. Papaioannou A, Kennedy CC, Ioannidis G, et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2008;19:581-7.
11. Austin PC, Tu JV, Ko DT, et al. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction. CMAJ 2008;179:901-8.
12. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:18-23.
13. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213.
14. Fitch K, Bernstein SJ, Aguilar MS, et al. The RAND/UCLA appropriateness method user's manual. Santa Monica (CA): The RAND Corporation; 2001.
15. Brown JP, Albert C, Nassar BA, et al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 2009;42:929-42.
16. Lentle BC, Brown JP, Khan A, et al. Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. Can Assoc Radiol J 2007;58:27-36. (Pubitemid 46348494)
17. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3. (Pubitemid 32095035)
18. Leslie WD, Berger C, Langsetmo L, et al. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba BMD cohorts. Osteoporos Int. In press.
19. Leslie WD, Lix LM, Langsetmo L, et al. Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int. In press.
20. Leslie WD, Lix LM, Johansson H, et al.; Manitoba Bone Density Program. Independent clinical validation of a Canadian FRAX((R)) tool: fracture prediction and model calibration. J Bone Miner Res 2010 Apr 30. [Epub ahead of print].
21. Leslie WD, Tsang JF, Lix LM; Manitoba Bone Density Program. Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J Bone Miner Res 2009;24:353-60.
22. Fraser L, Langsetmo L, Berger C, et al. Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos. Osteoporos Int. In press.
23. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral dens ity reporting in Canada. Can Assoc Radiol J 2005;56:178-88.
24. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-9.
25. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033-46.
26. Leslie WD, Lix LM, Johansson H, et al. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 2010. In press.
27. Li WC, Chen YC, Yang RS, et al. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis. Clin Rehabil 2009;23:888-96.
28. Moayyeri A. The association between physical activity and osteoporotic fractures: a review of the evidence and implications for future research. Ann Epidemiol 2008; 18: 827-35.
29. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009;(2):CD007146.
30. de Kam D, Smulders E, Weerdesteyn V, et al. Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials. Osteoporos Int 2009;20:2111-25.
31. Hip protectors in long-term care policy guidance and implementation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, Health Technology Inquiry Service; 2010.
32. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-66. (Pubitemid 47285316)
33. Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int 2008;19:1119-23.
34. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341: c3691.
35. Hanley DA, Cranney A, Jones G, et al.; Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). CMAJ 2010; 182:1315-9.
36. Cranney A, Guyatt G, Griffith L, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8.
37. Bolland MJ, Grey AB, Gamble GD, et al. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95:1174-81.
38. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
39. Knopp JA, Diner BM, Blitz M, et al. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 2005;16:1281-90. (Pubitemid 41396958)
40. Langdahl BL, Rajzbaum G, Jakob F, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93.
41. Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005;6:39.
42. Rahmani P, Morin S. Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ 2009;181:815-20.
43. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361: 756-65.
44. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.
45. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40.
46. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010 Sep 14. [Epub ahead of print].
47. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90.
48. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:1789; author reply 1791-2.
49. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444.
50. Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63.
51. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predict - ors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9.
52. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone dens - ity or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-15.
53. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multi centre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63.
54. Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;(2): CD001983.
55. Tsoi D, Khan A, Nowak AK, et al. Bisphosphonates for prevention of bone loss in women with early breast cancer. Cochrane Database Syst Rev 2009;(3): CD007914.
56. Hines SL, Sloan JA, Atherton PJ, et al. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aroma tase inhibitor therapy. Breast 2010;19:92-6.
57. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-82.
58. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.
59. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int 2008;19:1363-8.
60. Baim S, Wilson CR, Lewiecki EM, et al. Precision assessment and radiation safety for dual-energy x-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 2005;8:371-8.
61. Frost SA, Nguyen ND, Center JR, et al. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res 2009; 24: 1800-7.
62. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38.
63. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008;19:365-72. (Pubitemid 351199181)
64. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997;277:543-7.
65. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289:2525-33.
66. Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-92.
67. Tosteson AN, Melton LJ III, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008;19:437-47.
68. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-408.
69. Kastner M, Straus SE. Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials. J Gen Intern Med 2008;23:2095-105.
70. Majumdar SR, Beaupre LA, Harley CH, et al. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med 2007;167:2110-5.
71. Bogoch ER, Elliot-Gibson V, Beaton DE, et al. Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic en - vironment. J Bone Joint Surg Am 2006;88:25-34.